Key Developments: Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

14.12USD
10 Jul 2014
Price Change (% chg)

$-0.19 (-1.33%)
Prev Close
$14.31
Open
$13.75
Day's High
$14.68
Day's Low
$13.40
Volume
665,238
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Oncothyreon and Celldex Therapeutics announce collaboration for combination immunotherapy clinical trial of ONT-10 and varlilumab
Thursday, 29 May 2014 08:00am EDT 

Oncothyreon Inc and Celldex Therapeutics Inc:Says that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab.ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1.Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.Planned trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer.  Full Article

Bristol-Myers Squibb and Celldex Therapeutics announce clinical trial collaboration
Wednesday, 14 May 2014 08:00am EDT 

Bristol-Myers Squibb Co and Celldex Therapeutics Inc:Enters into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study.Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and neck cancers.Bristol-Myers Squibb will make a one-time payment of $5 mln to Celldex and the parties will share development costs.Celldex will be responsible for conducting the Ph 1/2 study, which is expected to begin in the fourth quarter of 2014.  Full Article

Celldex Therapeutics establishes preclinical proof of concept for New Antibody Drug Conjugate CDX-014
Monday, 7 Apr 2014 04:00pm EDT 

Celldex Therapeutics Inc:Reported results of preclinical studies evaluating anti-tumor activity of CDX-014 against variety of cell lines.Based on results, CDX-014 will enter clinical development.CDX-014 is antibody drug conjugate (ADC) that targets protein TIM-1 (T cell immunoglobulin and mucin domain).TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas.It is associated with kidney injury and shedding of its ectodomain is a predictive biomarker for tumor progression.TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy.  Full Article

Celldex Therapeutics Inc's CDX-301 in combination with Mozobil increases hematopoietic stem cell mobilization and results in improved transplantation of mobilized cells in preclinical studies
Tuesday, 10 Dec 2013 08:30am EST 

Celldex Therapeutics Inc:Says positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice.Says the data support future clinical development of CDX-301 and demonstrate a potent cell mobilization regimen combining CDX-301 and Mozobil, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation.Says results were presented in an oral session entitled FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome on Dec. 10 at the American Society of Hematology 55th Annual Meeting and Exposition (ASH).Says the studies were conducted in collaboration with Jianhua Yu, PhD, and Steven Devine, MD, and were presented by Shun He, PhD, all of The Ohio State University.Says this study found that the combination of CDX-301 and Mozobil mobilized the highest rate and amount of hematopoietic stem cells into peripheral blood compared to the mice treated with granulocyte colony-stimulating factor alone, or the combination of G-CSF with Mozobil.  Full Article

Celldex Therapeutics Inc announces exercise of underwriters' option to purchase additional shares
Monday, 9 Dec 2013 05:02pm EST 

Celldex Therapeutics Inc:Says the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,050,000 additional shares of common stock at the public offering price of $24.50.Says proceeds to Celldex from the exercise of the underwriters' option will be about $18.9 million, after deducting underwriting discounts and commissions and proceeds to a limited number of selling stockholders.Says 813,483 shares sold pursuant to the exercise of the option were sold by Celldex and 236,517 shares were sold by selling stockholders.Says the offering is expected to close on or about Dec. 10, subject to customary closing conditions.  Full Article

Celldex Therapeutics Inc prices public offering of common stock
Wednesday, 4 Dec 2013 07:51pm EST 

Celldex Therapeutics Inc:Says the pricing of an underwritten public offering of 7,000,000 shares of its common stock, offered at a price to the public of $24.50 per share for an aggregate offering of $171,500,000 of common stock.Says the net proceeds to Celldex from this offering are expected to be approximately $162,725,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex.Says the underwriters have been granted a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock.Says the offering is expected to close on or about Dec. 10.Says Jefferies LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Guggenheim Securities, Oppenheimer & Co. Inc., Wedbush PacGrow Life Sciences, Brean Capital, LLC, Cantor Fitzgerald & Co. and Roth Capital Partners are acting as co-managers of the offering.Says it anticipates using the net proceeds from the offering to fund Celldex's clinical trials of its product candidates and for working capital and other general corporate purposes.  Full Article

Celldex Therapeutics Inc announces proposed public offering of common stock
Tuesday, 3 Dec 2013 04:04pm EST 

Celldex Therapeutics Inc:Says it is offering 6.5 million shares of its common stock in a proposed underwritten public offering.Says the offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Says shares will be issued pursuant to a prospectus supplement to be filed as part of a shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3.Says Jefferies LLC and Leerink Swann LLC are acting as the joint book-running managers and underwriters for the proposed offering.  Full Article

Celldex Therapeutics Inc's Rindopepimut demonstrates promising clinical activity in patients with EGFRvIII-positive recurrent Glioblastoma
Sunday, 24 Nov 2013 01:25pm EST 

Celldex Therapeutics Inc:Reports interim data from its ongoing, exploratory Phase 2 ReACT study of rindopepimut in recurrent glioblastoma.Says Rindopepimut is an immunotherapeutic vaccine that targets the tumor specific oncogene EGFRvIII(v3).Says patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival.Says the ReACT results demonstrate promising signs of clinical activity in advanced patient populations, including patients both naïve and refractory to bevacizumab (Avastin).Says an update on long-term survival for the three completed Phase 2 frontline studies in EGFRvIII-positive glioblastoma was also presented and results continue to exceed outcomes seen in contemporary controls.  Full Article

Celldex Therapeutics Inc Announces Publication Of Preliminary Data From Phase 2 ReACT Study
Monday, 11 Nov 2013 07:01am EST 

Celldex Therapeutics Inc announced the preliminary data from ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma, was published in the 2013 abstract supplement to the journal Neuro-Oncology. ReACT is a Phase 2 study designed to determine if adding rindopepimut to standard of care Avastin (bevacizumab) improves the outcomes for patients with recurrent EGFRvIII-positive glioblastoma. In August, 2013, Celldex announced that enrollment had been completed in an initial cohort (n=25) of Avastin refractory patients and that, based on early evidence of anti-tumor activity, the Company decided to add an expansion cohort of approximately 75 patients (Group 2C) to better characterize the potential activity of rindopepimut in this refractory patient population. Study endpoints include six month progression free survival rate, objective response rate, overall survival and safety and tolerability.  Full Article

Celldex Therapeutics Inc Announces Exercise Of Underwriters' Option To Purchase Additional Shares
Friday, 8 Feb 2013 08:03am EST 

Celldex Therapeutics Inc announced that the underwriters of previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common stock at the public offering price of $7.50 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $12.7 million, after deducting underwriting discounts and commissions. The closing of the option exercise is expected to occur on February 11, 2013. As previously announced, Celldex anticipates using the net proceeds from the offering, including the net proceeds from the exercise of the option to purchase additional shares, to fund Celldex's clinical trials of product candidates and for working capital and other general corporate purposes. Jefferies & Company, Inc. and Leerink Swann LLC acted as joint book-running managers of the offering. Oppenheimer & Co., Wedbush PacGrow Life Sciences, Brean Capital and Roth Capital Partners, LLC acted as co-managers of the offering.  Full Article

Search Stocks